Skip to main content

Mersana Therapeutics’s stock craters after FDA halts trials of ovarian cancer treatment after patient deaths

Mersana's stock tumbles 58% to mark its biggest-ever one-day percentage decline since going public in 2018.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.